Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
about
Activation of DNA Damage Response Induced by the Kaposi's Sarcoma-Associated Herpes VirusBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesA liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or densityAnthracycline Drugs on Modified Surface of Quercetin-Loaded Polymer Nanoparticles: A Dual Drug Delivery Model for Cancer TreatmentNanotechnology in the war against cancer: new arms against an old enemy - a clinical view.Modeling of nanotherapeutics delivery based on tumor perfusion.Combinatorial peptide libraries: mining for cell-binding peptides.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsNanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.Characterization of the two-component monooxygenase system AlnT/AlnH reveals early timing of quinone formation in alnumycin biosynthesisLC-MS/MS method development for quantification of doxorubicin and its metabolite 13-hydroxy doxorubicin in mice biological matrices: Application to a pharmaco-delivery study.Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier.TAK1 ubiquitination regulates doxorubicin-induced NF-κB activation.Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerDevelopment of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo.Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing modelNanoreporter PET predicts the efficacy of anti-cancer nanotherapy.Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticlesUse of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsGemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Pegylated liposomal doxorubicin: a guide to its use in various malignancies.The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes.Nanotechnology applications in diagnosis and treatment of metastasis.Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: preparation, characterization, and in vitro cytotoxicity studies.Liposomal doxorubicin doubly functionalized with CCK8 and R8 peptide sequences for selective intracellular drug delivery.Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.Zirconium phosphate nanoplatelets: a biocompatible nanomaterial for drug delivery to cancer.Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.Development of redox-sensitive red fluorescent proteins for imaging redox dynamics in cellular compartments.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
P2860
Q26743368-26322A5B-C339-4B0A-93CD-3A9109D2B92BQ26783705-19BE772D-94A8-4083-A1CE-51E4176F1ED4Q27308658-3298A449-0294-4D42-90D6-11BFC9B04910Q28552231-18784FB2-D79F-4D7E-B351-5FAD5D5C1F58Q30376531-ED41D585-6527-48CB-84FA-14E5EF70AD25Q30544603-77095181-BEC7-495F-A9CC-A231BA880CE8Q31144876-94A57106-C454-409B-B779-3CF012925950Q33409319-A17373AE-E134-4873-8492-4FE90F9528F0Q33418086-AD06AC28-9BDB-41D3-B2A7-724781648EA0Q33600072-CAA03E1F-9F4A-4A13-A696-46DD06AFD004Q34146337-10B93A54-327A-4299-8CB8-03A27F3B7EEBQ35674158-7119ED35-0E26-4312-80CE-6EA6615BDC30Q36018354-129FAFD5-E0F4-498F-944A-29DA54AD05F5Q36156185-FD88DA5C-EBEB-4AED-84DE-6DD6CD90401DQ36217918-FC238782-F24E-40D0-B37F-BFBEF856E34BQ36429055-532FDD12-48BE-4C7E-B2FB-CFB9B6D795D8Q36728989-D177667E-AAC1-4E10-A2FF-FCDC84F11966Q36944149-625BC40C-38DA-4C5C-B4AE-B16DD998AF08Q36996565-BCA25590-6BBE-489F-A4E8-C823EC9F3E34Q37024507-B53C689A-82E2-42C5-8A5E-53D89C36D26FQ37141366-77E13028-B51F-4322-8782-760DA7C6DAABQ37518724-ED805CF9-D25C-4732-B0E9-89F1E7B87CA9Q37602839-0A7384F5-AAEE-4A32-BB50-F9FC7BD4AA2FQ37712444-36C1F316-280E-4438-9B4B-7E53FCF2FC0AQ38042256-BEFC7A89-AE91-49DA-BA25-567DFCD7FA3FQ38058785-64A38175-36DC-4B98-B99B-8F061E7F7332Q38135689-B74AE5B5-29BC-49FA-80FE-94FC3638AB7EQ38247429-89D82820-9D7C-4A17-9DB1-46E0F6FF3197Q38254086-C31D240E-30B0-4FF2-86CB-DC21C539F98BQ38502588-5363ECF9-BF7B-42C8-8567-5B50AE71E7C2Q38577297-6F8807ED-51A2-40AB-9ACB-25B53F8C4CC4Q38760799-09714FD0-37CD-4BB7-898B-F545BBF7733AQ38901825-62741BED-CE11-40CC-A04F-414740350AD2Q38973056-1BC99B05-F92D-43B8-87A4-D44AE8FEA6E9Q39197837-6E6D8936-1F6C-4A75-A54C-4F55059932EFQ39268019-F73575A5-5173-4172-862C-2A27048C7165Q40485087-F71DC6F5-9437-4417-BE1A-DB5A8244098FQ42052611-1AB9E083-366B-4A92-9069-AE36015E31D2Q42487387-A60D73D8-910A-4D98-8F89-C49D3B667497Q45073135-00A8D062-3940-4195-8316-54384748151F
P2860
Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@en
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@nl
type
label
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@en
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@nl
prefLabel
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@en
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@nl
P2860
P1433
P1476
Pegylated liposomal doxorubici ...... AIDS-related Kaposi's sarcoma.
@en
P2093
Sean T Duggan
P2860
P304
P356
10.2165/11207510-000000000-00000
P577
2011-12-01T00:00:00Z
P6179
1047041341